Study wrapper · #965
Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.
Chung CW, Kim J Journal of obesity & metabolic syndrome. 2026.
DOI: 10.7570/jomes25085PubMed: 41549439
Editor's note
A narrative review summarizing the amylin pathway and its analogs for obesity and type 2 diabetes. Cagrilintide and semaglutide feature as the peptide-relevant agents, with combination therapy associated with weight loss exceeding 15% in trials. Useful as background context rather than primary evidence.
Plain-language abstract
This review discusses amylin biology and the amylin analog cagrilintide, which has been studied for weight loss in obesity, including in combination with semaglutide.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinologyn=——2026
Supported
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)n=——2026